CoChat
Sign Up
Cited by 41Liver Disease Diagnosis and TreatmentDiabetes Treatment and ManagementLiver physiology and pathology

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD

Open access
Petrovic, Ana, Igrec, Dunja, Rozac, Karla, Bojanic, Kristina, Kuna, Lucija, Kolaric, Tea Omanovic, Mihaljevic, Vjera, Sikora, Renata +4 more·2023·Current Issues in Molecular Biology
DOI 10.3390/cimb45060288PMC PMC10296833
Open this paper in CoChat — free accountOpen PDF

Abstract

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been shown to improve glucose and lipid homeostasis, promote weight loss, and reduce cardiovascular risk factors. They are a promising therapeutic option for non-alcoholic fatty liver disease (NAFLD), the most common liver disease, associated with T2DM, obesity, and metabolic syndrome. GLP-1RAs have been approved for the treatment of T2DM and obesity, but not for NAFLD. Most recent clinical trials have suggested the importance of early pharmacologic intervention with GLP-1RAs in alleviating and limiting NAFLD, as well as highlighting the relative scarcity of in vitro studies on semaglutide, indicating the need for further research. However, extra-hepatic factors contribute to the GLP-1RA results of in vivo studies. Cell culture models of NAFLD can be helpful in eliminating extrahepatic effects on the alleviation of hepatic steatosis, modulation of lipid metabolism pathways, reduction of inflammation, and prevention of the progression of NAFLD to severe hepatic conditions. In this review article, we discuss the role of GLP-1 and GLP-1RA in the treatment of NAFLD using human hepatocyte models.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cimb45060288

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • GLP-1RAs play a limited role in lipid management, suggesting that additional lipid-lowering therapies may be necessary for comprehensive metabolic control.

    “This highlights the limited role that GLP-1RAs play in lipid management, suggesting that additional lipid-lowering therapies may be necessary for comprehensive metabolic control27–29.”

    From Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials (2025) · cites this paper as [27]

    The Conclusions (page unavailable) describe GLP-1RAs as highly efficient at modulating hepatic steatosis and lipid-related pathways in NAFLD models, contrary to the claim that their role in lipid management is limited. The paper discusses lifestyle changes as adjuncts but does not recommend additional lipid-lowering therapies for comprehensive metabolic control. (LLM, conf=0.86)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 94 · Cited by 41

Research works printed but not linked: 77

  1. [1]Riazi K. Azhari H. Charette J.H. Underwood F.E. King J.A. Afshar E.E. Swain M.G. Congly S.E. Kaplan G.G. Shaheen A.A. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis Lancet Gastroenterol. Hepatol. 2022 7 851 861 10.1016/S2468-1253(22)00165-0 35798021 · DOI · Paper page
  2. [2]Teng M.L. Ng C.H. Huang D.Q. Chan K.E. Tan D.J. Lim W.H. Yang J.D. Tan E. Muthiah M.D. Global incidence and prevalence of nonalcoholic fatty liver disease Clin. Mol. Hepatol. 2023 29 S32 S42 10.3350/cmh.2022.0365 36517002 PMC10029957 · DOI · Paper page
  3. [3]Kumar R. Priyadarshi R.N. Anand U. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations J. Clin. Transl. Hepatol. 2020 8 76 86 10.14218/JCTH.2019.00051 32274348 PMC7132013 · DOI
  4. [4]Buzzetti E. Pinzani M. Tsochatzis E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) Metabolism 2016 65 1038 1048 10.1016/j.metabol.2015.12.012 26823198 · DOI · Paper page
  5. [5]Holst J.J. The physiology of glucagon-like peptide 1 Physiol. Rev. 2007 87 1409 1439 10.1152/physrev.00034.2006 17928588 · DOI · Paper page
  6. [6]Crunkhorn S. Illuminating the incretin effect Nat. Rev. Endocrinol. 2021 Available online: https://www.nature.com/articles/d42859-021-00012-3 (accessed on 23 April 2023)
  7. [9]Knop F.K. Aaboe K. Vilsbøll T. Vølund A. Holst J.J. Krarup T. Madsbad S. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity Diabetes Obes. Metab. 2012 14 500 510 10.1111/j.1463-1326.2011.01549.x 22171657 · DOI
  8. [10]Hare K.J. Vilsbøll T. Holst J.J. Knop F.K. Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes Am. J. Physiol. Endocrinol. Metab. 2010 298 E832 E837 10.1152/ajpendo.00700.2009 20103744 · DOI
  9. [11]Dupre J. Glycaemic effects of incretins in Type 1 diabetes mellitus: A concise review, with emphasis on studies in humans Regul. Pept. 2005 128 149 157 10.1016/j.regpep.2004.06.003 15780434 · DOI
  10. [12]Michałowska J. Miller-Kasprzak E. Bogdański P. Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective Nutrients 2021 13 351 10.3390/nu13020351 33503878 PMC7910956 · DOI
  11. [14]Junker A.E. The role of incretin hormones and glucagon in patients with liver disease Dan. Med. J. 2017 64 B5363 28552096
  12. [15]Kuhre R.E. Deacon C.F. Holst J.J. Petersen N. What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell? Front. Endocrinol. 2021 12 694284 10.3389/fendo.2021.694284 PMC8218725 34168620 · DOI
  13. [17]Nauck M.A. Quast D.R. Wefers J. Pfeiffer A.F.H. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update Diabetes Obes. Metab. 2021 23 (Suppl. S3) 5 29 10.1111/dom.14496 34310013 · DOI · Paper page
  14. [20]Lyu J. Imachi H. Fukunaga K. Sato S. Kobayashi T. Dong T. Saheki T. Matsumoto M. Iwama H. Zhang H. Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes Mol. Metab. 2020 34 16 26 10.1016/j.molmet.2019.12.015 32180556 PMC6997505 · DOI
  15. [21]Gupta N.A. Mells J. Dunham R.M. Grakoui A. Handy J. Saxena N.K. Anania F.A. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway Hepatology 2010 51 1584 1592 10.1002/hep.23569 20225248 PMC2862093 · DOI · Paper page
  16. [22]Yokomori H. Ando W. Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis BMJ Open Gastroenterol. 2020 7 e000370 10.1136/bmjgast-2019-000370 32414752 PMC7232783 · DOI
  17. [24]Thorens B. Porret A. Bühler L. Deng S.P. Morel P. Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor Diabetes 1993 42 1678 1682 10.2337/diab.42.11.1678 8405712 · DOI
  18. [25]Mells J.E. Anania F.A. The role of gastrointestinal hormones in hepatic lipid metabolism Semin. Liver Dis. 2013 33 343 357 10.1055/s-0033-1358527 24222092 PMC3956077 · DOI
  19. [26]Omanovic Kolaric T. Kizivat T. Mihaljevic V. Zjalic M. Bilic-Curcic I. Kuna L. Smolic R. Vcev A. Wu G.Y. Smolic M. Liraglutide Exerts Protective Effects by Downregulation of PPARγ, ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis and Drug-Induced Steatosis Curr. Issues Mol. Biol. 2022 44 3465 3480 10.3390/cimb44080239 36005135 PMC9406665 · DOI
  20. [28]Pechenov S. Revell J. Will S. Naylor J. Tyagi P. Patel C. Liang L. Tseng L. Huang Y. Rosenbaum A.I. Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease Sci. Rep. 2021 11 22521 10.1038/s41598-021-01750-0 34795324 PMC8602401 · DOI
  21. [29]Knudsen L.B. Lau J. The Discovery and Development of Liraglutide and Semaglutide Front. Endocrinol. 2019 10 155 10.3389/fendo.2019.00155 PMC6474072 31031702 · DOI · Paper page
  22. [30]Idrees Z. Cancarevic I. Huang L. FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade Cureus 2022 14 e29262 10.7759/cureus.29262 36277516 PMC9579826 · DOI
  23. [31]Ghosal S. Datta D. Sinha B. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D) Sci. Rep. 2021 11 22063 10.1038/s41598-021-01663-y 34764398 PMC8586228 · DOI
  24. [32]Wong C. Lee M.H. Yaow C.Y.L. Chin Y.H. Goh X.L. Ng C.H. Lim A.Y.L. Muthiah M.D. Khoo C.M. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis Front. Endocrinol. 2021 12 609110 10.3389/fendo.2021.609110 33897616 PMC8063104 · DOI
  25. [33]Zhang F. Chen Z. Wu D. Tian L. Chen Q. Ye Y. Chen W. Wu X. Wu P. Yuan W. Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice iScience 2021 24 103382 10.1016/j.isci.2021.103382 34841227 PMC8605346 · DOI · Paper page
  26. [34]Drucker D.J. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 Cell Metab. 2018 27 740 756 10.1016/j.cmet.2018.03.001 29617641 · DOI · Paper page
  27. [35]Kalogirou M.S. Patoulias D. Haidich A.B. Akriviadis E. Sinakos E. Liraglutide in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials Clin. Res. Hepatol. Gastroenterol. 2021 45 101568 10.1016/j.clinre.2020.10.012 33309563 · DOI
  28. [36]Xie Z. Yang S. Deng W. Li J. Chen J. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review Clin. Epidemiol. 2022 14 1463 1476 10.2147/CLEP.S391819 36510488 PMC9738168 · DOI · Paper page
  29. [37]Verma S. Bhatt D.L. Bain S.C. Buse J.B. Mann J.F.E. Marso S.P. Nauck M.A. Poulter N.R. Pratley R.E. Zinman B. Effect of Liraglutide on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial Circulation 2018 137 2179 2183 10.1161/CIRCULATIONAHA.118.033898 29760228 · DOI · Paper page
  30. [38]Singh G. Krauthamer M. Bjalme-Evans M. Wegovy (semaglutide): A new weight loss drug for chronic weight management J. Investig. Med. 2022 70 5 13 10.1136/jim-2021-001952 PMC8717485 34706925 · DOI
  31. [39]Girdhar K. Dehury B. Kumar Singh M. Daniel V.P. Choubey A. Dogra S. Kumar S. Mondal P. Novel insights into the dynamics behavior of glucagon-like peptide-1 receptor with its small molecule agonists J. Biomol. Struct. Dyn. 2019 37 3976 3986 10.1080/07391102.2018.1532818 30296922 · DOI
  32. [41]Jianping W. Xuelian Z. Anjiang W. Haiying X. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Metabolic Associated Fatty Liver Disease: A Systematic Review and Meta-analysis J. Clin. Gastroenterol. 2021 55 586 593 10.1097/MCG.0000000000001556 34039937 · DOI
  33. [42]Barritt A.S. Marshman E. Noureddin M. Review article: Role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know Aliment. Pharmacol. Ther. 2022 55 944 959 10.1111/apt.16794 35266164 PMC9310586 · DOI
  34. [43]Yaribeygi H. Maleki M. Butler A.E. Jamialahmadi T. Sahebkar A. The Impact of Incretin-Based Medications on Lipid Metabolism J. Diabetes Res. 2021 2021 1815178 10.1155/2021/1815178 35005028 PMC8731296 · DOI
  35. [47]Armstrong M. Hull D. Guo K. Barton D. Yu J. Tomlinson J. Newsome P. Effect of liraglutide on adipose insulin resistance and hepatic de-novo lipogenesis in non-alcoholic steatohepatitis: Substudy of a phase 2, randomised placebo-controlled trial Lancet 2014 383 S21 10.1016/S0140-6736(14)60284-1 · DOI
  36. [49]Khalifa O. Al-Akl N.S. Errafii K. Arredouani A. Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway Sci. Rep. 2022 12 2226 10.1038/s41598-022-06143-5 35140289 PMC8828858 · DOI
  37. [51]Sookoian S. Pirola C.J. Valenti L. Davidson N.O. Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology Hepatology 2020 72 330 346 10.1002/hep.31229 32170962 PMC7363530 · DOI
  38. [52]Moya M. Benet M. Guzmán C. Tolosa L. García-Monzón C. Pareja E. Castell J.V. Jover R. Foxa1 reduces lipid accumulation in human hepatocytes and is down-regulated in nonalcoholic fatty liver PLoS ONE 2012 7 e30014 10.1371/journal.pone.0030014 22238690 PMC3253125 · DOI
  39. [53]Guzmán C. Benet M. Pisonero-Vaquero S. Moya M. García-Mediavilla M.V. Martínez-Chantar M.L. González-Gallego J. Castell J.V. Sánchez-Campos S. Jover R. The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARα; and repressed by C/EBPα: Implications in FABP1 down-regulation in nonalcoholic fatty liver disease Biochim. Biophys. Acta 2013 1831 803 818 10.1016/j.bbalip.2012.12.014 23318274 · DOI
  40. [54]Fang C. Pan J. Qu N. Lei Y. Han J. Zhang J. Han D. The AMPK pathway in fatty liver disease Front. Physiol. 2022 13 970292 10.3389/fphys.2022.970292 36203933 PMC9531345 · DOI · Paper page
  41. [55]Miao R. Fang X. Wei J. Wu H. Wang X. Tian J. Akt: A Potential Drug Target for Metabolic Syndrome Front. Physiol. 2022 13 822333 10.3389/fphys.2022.822333 35330934 PMC8940245 · DOI
  42. [56]Jin L. Sun Y. Li Y. Zhang H. Yu W. Xin Y. Alsareii S.A. Wang Q. Zhang D. A synthetic peptide AWRK6 ameliorates metabolic associated fatty liver disease: Involvement of lipid and glucose homeostasis Peptides 2021 143 170597 10.1016/j.peptides.2021.170597 34118361 · DOI
  43. [57]Yu P. Xu X. Zhang J. Xia X. Xu F. Weng J. Lai X. Shen Y. Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway Int. J. Endocrinol. 2019 2019 1567095 10.1155/2019/1567095 31236111 PMC6545813 · DOI
  44. [58]Sharma Y. Ahmad A. Yavvari P.S. Kumar Muwal S. Bajaj A. Khan F. Targeted SHP-1 Silencing Modulates the Macrophage Phenotype, Leading to Metabolic Improvement in Dietary Obese Mice Mol. Ther. Nucleic Acids 2019 16 626 636 10.1016/j.omtn.2019.04.020 31108319 PMC6526246 · DOI
  45. [59]Dubois M.J. Bergeron S. Kim H.J. Dombrowski L. Perreault M. Fournès B. Faure R. Olivier M. Beauchemin N. Shulman G.I. The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis Nat. Med. 2006 12 549 556 10.1038/nm1397 16617349 · DOI
  46. [60]Lin L. Jian J. Song C.Y. Chen F. Ding K. Xie W.F. Hu P.F. SHP-1 ameliorates nonalcoholic steatohepatitis by inhibiting proinflammatory cytokine production FEBS Lett. 2020 594 2965 2974 10.1002/1873-3468.13879 32619269 · DOI
  47. [61]Xu E. Forest M.P. Schwab M. Avramoglu R.K. St-Amand E. Caron A.Z. Bellmann K. Shum M. Voisin G. Paquet M. Hepatocyte-specific Ptpn6 deletion promotes hepatic lipid accretion, but reduces NAFLD in diet-induced obesity: Potential role of PPARγ Hepatology 2014 59 1803 1815 10.1002/hep.26957 24327268 · DOI
  48. [62]Li S. Wang X. Zhang J. Li J. Liu X. Ma Y. Han C. Zhang L. Zheng L. Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease Braz. J. Med. Biol. Res. 2018 51 e7299 10.1590/1414-431x20187299 29924135 PMC6010322 · DOI
  49. [63]Favari E. Chroni A. Tietge U.J. Zanotti I. Escolà-Gil J.C. Bernini F. Cholesterol efflux and reverse cholesterol transport Handb. Exp. Pharmacol. 2015 224 181 206 10.1007/978-3-319-09665-0_4 25522988 · DOI
  50. [64]Yousefi B. Darabi M. Baradaran B. Khaniani M.S. Rahbani M. Fayezi S. Mehdizadeh A. Saliani N. Shaaker M. Inhibition of MEK/ERK1/2 Signaling Affects the Fatty Acid Composition of HepG2 Human Hepatic Cell Line Bioimpacts 2012 2 145 150 10.5681/bi.2012.019 23678452 PMC3648933 · DOI
  51. [65]Kassouf T. Sumara G. Impact of Conventional and Atypical MAPKs on the Development of Metabolic Diseases Biomolecules 2020 10 1256 10.3390/biom10091256 32872540 PMC7563211 · DOI
  52. [66]Wu Y.R. Shi X.Y. Ma C.Y. Zhang Y. Xu R.X. Li J.J. Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway Cardiovasc. Diabetol. 2019 18 146 10.1186/s12933-019-0954-6 31706303 PMC6842145 · DOI
  53. [67]Schulze R.J. Krueger E.W. Weller S.G. Johnson K.M. Casey C.A. Schott M.B. McNiven M.A. Direct lysosome-based autophagy of lipid droplets in hepatocytes Proc. Natl. Acad. Sci. USA 2020 117 32443 32452 10.1073/pnas.2011442117 33288726 PMC7768785 · DOI
  54. [69]He Y. Ao N. Yang J. Wang X. Jin S. Du J. The preventive effect of liraglutide on the lipotoxic liver injury via increasing autophagy Ann. Hepatol. 2020 19 44 52 10.1016/j.aohep.2019.06.023 31787541 · DOI
  55. [70]Zhang Q. Liu Q. Niu C.Y. Liraglutide alleviates lipotoxic liver cell damage and promotes autophagy to improve non-alcoholic fatty liver Zhonghua Gan Zang Bing Za Zhi 2021 29 456 461 10.3760/cma.j.cn501113-20200427-00219 34107584 PMC12814099 · DOI
  56. [71]Arroyave-Ospina J.C. Wu Z. Geng Y. Moshage H. Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy Antioxidants 2021 10 174 10.3390/antiox10020174 33530432 PMC7911109 · DOI
  57. [72]Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: Pathophysiology and clinical implications Gastroenterology 2012 142 711 725.e6 10.1053/j.gastro.2012.02.003 22326434 · DOI
  58. [73]Huang C. Yuan L. Cao S. Endogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets Int. J. Mol. Med. 2015 36 173 185 10.3892/ijmm.2015.2207 25976560 PMC4494597 · DOI · Paper page
  59. [74]Somm E. Montandon S.A. Loizides-Mangold U. Gaïa N. Lazarevic V. De Vito C. Perroud E. Bochaton-Piallat M.-L. Dibner C. Schrenzel J. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet Transl. Res. 2021 227 75 88 10.1016/j.trsl.2020.07.008 32711187 · DOI · Paper page
  60. [75]Liu Y. Wang D.W. Wang D. Duan B.H. Kuang H.Y. Exenatide Attenuates Non-Alcoholic Steatohepatitis by Inhibiting the Pyroptosis Signaling Pathway Front. Endocrinol. 2021 12 663039 10.3389/fendo.2021.663039 PMC8092357 33953700 · DOI
  61. [76]Zhu W. Feng P.P. He K. Li S.W. Gong J.P. Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet Biochem. Biophys. Res. Commun. 2018 505 523 529 10.1016/j.bbrc.2018.09.134 30269815 · DOI
  62. [77]Li Z. Feng P.P. Zhao Z.B. Zhu W. Gong J.P. Du H.M. Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway Biochem. Biophys. Res. Commun. 2019 510 20 26 10.1016/j.bbrc.2018.12.149 30683312 · DOI
  63. [78]Ji J. Feng M. Huang Y. Niu X. Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro Bioengineered 2022 13 5091 5102 10.1080/21655979.2022.2036902 35164657 PMC8974036 · DOI
  64. [79]Ao N. Ma Z. Yang J. Jin S. Zhang K. Luo E. Du J. Liraglutide ameliorates lipotoxicity-induced inflammation through the mTORC1 signalling pathway Peptides 2020 133 170375 10.1016/j.peptides.2020.170375 32771373 · DOI
  65. [80]Feng J. Qiu S. Zhou S. Tan Y. Bai Y. Cao H. Guo J. Su Z. mTOR: A Potential New Target in Nonalcoholic Fatty Liver Disease Int. J. Mol. Sci. 2022 23 9196 10.3390/ijms23169196 36012464 PMC9409235 · DOI
  66. [81]Chen H. Nutrient mTORC1 signaling contributes to hepatic lipid metabolism in the pathogenesis of non-alcoholic fatty liver disease Liver Res. 2020 4 15 22 10.1016/j.livres.2020.02.004 · DOI
  67. [82]Titchenell P.M. Lazar M.A. Birnbaum M.J. Unraveling the Regulation of Hepatic Metabolism by Insulin Trends Endocrinol. Metab. 2017 28 497 505 10.1016/j.tem.2017.03.003 28416361 PMC5477655 · DOI
  68. [83]Chen Z. Yu R. Xiong Y. Du F. Zhu S. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease Lipids Health Dis. 2017 16 203 10.1186/s12944-017-0572-9 29037210 PMC5644081 · DOI
  69. [84]Wang Y. Song X. Wang N. Specific interaction of insulin receptor and GLP-1 receptor mediates crosstalk between their signaling Biochem. Biophys. Res. Commun. 2022 636 31 39 10.1016/j.bbrc.2022.10.094 36343488 · DOI
  70. [86]Yan H. Huang C. Shen X. Li J. Zhou S. Li W. GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis Front. Endocrinol. 2022 13 923606 10.3389/fendo.2022.923606 PMC9325993 35909522 · DOI
  71. [87]Czech T.Y. Wang Q. Seki E. A new mechanism of action of glucagon-like peptide-1 agonist in hepatic steatosis: Promotion of hepatic insulin clearance through induction of carcinoembryonic antigen-related cell adhesion molecule 1 Hepatol. Commun. 2018 2 9 12 10.1002/hep4.1147 29404506 PMC5776878 · DOI
  72. [88]Zhao Y. Zhao W. Bu H. Toshiyoshi M. Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs Medicine 2023 102 e32892 10.1097/MD.0000000000032892 36820578 PMC9907937 · DOI
  73. [89]Song T. Jia Y. Li Z. Wang F. Ren L. Chen S. Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis Diabetes Ther. 2021 12 1735 1749 10.1007/s13300-021-01072-4 34002333 PMC8179869 · DOI
  74. [90]Loomba R. Abdelmalek M.F. Armstrong M.J. Jara M. Kjær M.S. Krarup N. Lawitz E. Ratziu V. Sanyal A.J. Schattenberg J.M. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: A randomised, placebo-controlled phase 2 trial Lancet Gastroenterol. Hepatol. 2023 8 511 522 10.1016/S2468-1253(23)00068-7 36934740 PMC10792518 · DOI · Paper page
  75. [91]Armstrong M.J. Gaunt P. Aithal G.P. Barton D. Hull D. Parker R. Hazlehurst J.M. Guo K. Abouda G. Aldersley M.A. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study Lancet 2016 387 679 690 10.1016/S0140-6736(15)00803-X 26608256 · DOI · Paper page
  76. [92]Newsome P.N. Buchholtz K. Cusi K. Linder M. Okanoue T. Ratziu V. Sanyal A.J. Sejling A.S. Harrison S.A. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis N. Engl. J. Med. 2021 384 1113 1124 10.1056/NEJMoa2028395 33185364 · DOI · Paper page
  77. [93]Yuen C. Yu T. French S. Marcus E.A. Yeh J. Chiu H. Treatment of an Adolescent Female With Nonalcoholic Steatohepatitis–Related Cirrhosis with Liraglutide JPGN Rep. 2023 4 e303 10.1097/PG9.0000000000000303 37200728 PMC10187831 · DOI

Authors
Petrovic, A., Igrec, D., Rozac, K., Bojanic, K., Kuna, L., Kolaric, T. O., Mihaljevic, V., Sikora, R., Smolic, R., Glasnovic, M., Wu, G. Y., & Smolic, M.
Affiliations
  • University of Osijek (HR)
  • Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia
  • Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia
  • UConn Health (US)
ORCID
Venue
Current Issues in Molecular Biology
Publisher
MDPI AG
Published
2023-05-24
Volume
45
Issue
6
Pages
4544-4556
ISSN
  • 1467-3037 (ISSN-L)
  • 1467-3045
DOI
10.3390/cimb45060288
PMC
PMC10296833
OpenAlex
W4378220347
Cited by
41
References
94
Citations by year
2026: 13 · 2025: 13 · 2024: 13 · 2023: 2
FWCI
1.60
Type
journal article
Language
en
Open access
Licence
Locations
  • Current Issues in Molecular Biology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
GLP-1 receptor agonists, non-alcoholic fatty liver disease, lipid metabolism, hepatic steatosis, semaglutide, liver inflammation, type 2 diabetes, obesity, metabolic syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review